Literature DB >> 26316905

Predictors of referral for neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer and changes in practice over time.

Geoffrey T Gotto1, Melissa A Shea-Budgell2, M Sarah Rose3, J Dean Ruether2.   

Abstract

INTRODUCTION: In patients with non-metastatic muscle-invasive bladder cancer (MIBC) fit for curative therapy, a multidisciplinary approach consisting is recommended. This approach includes local treatment (usually radical cystectomy), ideally combined with neoadjuvant chemotherapy (NACT). Despite a survival benefit with NACT, uptake remains low. We assessed NACT consultation in Alberta and examined associative factors, as well as the relationship to survival.
METHODS: Patients with MIBC were identified through the Alberta Cancer Registry. Demographic and clinicopathologic information was collected from electronic medical records between 2007 and 2011. In addition to descriptive statistics, logistic regression was used to determine factors associated with receiving NACT consultation. Overall survival was described using a Kaplan-Meier estimate.
RESULTS: Of the 315 radical cystectomy patients, 140 (45.1%, 95% confidence interval [CI] 39.5, 50.8) received NACT consultation. Patients ≥80 years (odds ratio [OR] 0.21, 95% CI 0.08, 0.57, p = 0.002) and those treated in Calgary (OR 0.11, 95% CI 0.05, 0.25, p < 0.001) were less likely to receive NACT consultation. The rate of NACT consultation increased steadily from 2007 to 2011 (OR 1.23, 95% CI 1.04, 1.45 per year of diagnosis, p = 0.018). After a median follow-up of 28.1 months (range: 14.6-50.3), median survival was 54.7 months for patients who received NACT consultation versus 31.2 months for those who did not (p = 0.030).
CONCLUSIONS: NACT consultation in patients with MIBC undergoing radical cystectomy has improved over time; however, regional differences underscore the need for a standardized approach to NACT consultation, including common referral mechanisms.

Entities:  

Year:  2015        PMID: 26316905      PMCID: PMC4537332          DOI: 10.5489/cuaj.2722

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN: 1911-6470            Impact factor:   1.862


  24 in total

1.  Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.

Authors:  D L Lamm; B A Blumenstein; J D Crissman; J E Montie; J E Gottesman; B A Lowe; M F Sarosdy; R D Bohl; H B Grossman; T M Beck; J T Leimert; E D Crawford
Journal:  J Urol       Date:  2000-04       Impact factor: 7.450

2.  Impact of provider volume on operative mortality after radical cystectomy in a publicly funded healthcare system.

Authors:  Girish S Kulkarni; David R Urbach; Peter C Austin; Neil E Fleshner; Andreas Laupacis
Journal:  Can Urol Assoc J       Date:  2013 Nov-Dec       Impact factor: 1.862

3.  Neoadjuvant chemotherapy should be administered to fit patients with newly diagnosed, potentially resectable muscle-invasive urothelial cancer of the bladder (MIBC): A 2013 CAGMO Consensus Statement and Call for a Streamlined Referral Process.

Authors:  Jo-An Seah; Normand Blais; Scott North; Yasmin Rahim; Dean Ruether; Peter C Black; Alexandre R Zlotta; Lori Wood; Srikala S Sridhar
Journal:  Can Urol Assoc J       Date:  2013 Sep-Oct       Impact factor: 1.862

4.  A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience.

Authors:  Atreya Dash; Joseph A Pettus; Harry W Herr; Bernard H Bochner; Guido Dalbagni; S Machele Donat; Paul Russo; Mary G Boyle; Matthew I Milowsky; Dean F Bajorin
Journal:  Cancer       Date:  2008-11-01       Impact factor: 6.860

5.  Patterns of referral for perioperative chemotherapy among patients with muscle-invasive bladder cancer: a population-based study.

Authors:  Christopher M Booth; David Robert Siemens; Yingwei Peng; William J Mackillop
Journal:  Urol Oncol       Date:  2014-06-23       Impact factor: 3.498

6.  Use of potentially curative therapies for muscle-invasive bladder cancer in the United States: results from the National Cancer Data Base.

Authors:  Phillip J Gray; Stacey A Fedewa; William U Shipley; Jason A Efstathiou; Chun Chieh Lin; Anthony L Zietman; Katherine S Virgo
Journal:  Eur Urol       Date:  2012-11-19       Impact factor: 20.096

7.  Validation of the AJCC TNM substaging of pT2 bladder cancer: deep muscle invasion is associated with significantly worse outcome.

Authors:  Derya Tilki; Oliver Reich; Pierre I Karakiewicz; Giacomo Novara; Wassim Kassouf; Süleyman Ergün; Yves Fradet; Vincenzo Ficarra; Guru Sonpavde; Christian G Stief; Eila Skinner; Robert S Svatek; Yair Lotan; Arthur I Sagalowsky; Shahrokh F Shariat
Journal:  Eur Urol       Date:  2010-01-20       Impact factor: 20.096

8.  Retrospective analysis of clinical outcomes with neoadjuvant cisplatin-based regimens for muscle-invasive bladder cancer.

Authors:  Sumanta K Pal; Nora H Ruel; Timothy G Wilson; Bertram E Yuh
Journal:  Clin Genitourin Cancer       Date:  2012-09-13       Impact factor: 2.872

Review 9.  Integration of neoadjuvant and adjuvant chemotherapy and cystectomy in the treatment of muscle-invasive bladder cancer.

Authors:  Matthew I Milowsky; Walter M Stadler; Dean F Bajorin
Journal:  BJU Int       Date:  2008-11       Impact factor: 5.588

10.  EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines.

Authors:  J Alfred Witjes; Eva Compérat; Nigel C Cowan; Maria De Santis; Georgios Gakis; Thierry Lebret; Maria J Ribal; Antoine G Van der Heijden; Amir Sherif
Journal:  Eur Urol       Date:  2013-12-12       Impact factor: 20.096

View more
  5 in total

1.  Low compliance with guidelines for re-staging in high-grade T1 bladder cancer and the potential impact on patient outcomes in the province of Alberta.

Authors:  Geoffrey T Gotto; Melissa A Shea-Budgell; J Dean Ruether
Journal:  Can Urol Assoc J       Date:  2016 Jan-Feb       Impact factor: 1.862

2.  Suboptimal use of neoadjuvant chemotherapy in radical cystectomy patients: A population-based study.

Authors:  Jonas Schiffmann; Maxine Sun; Giorgio Gandaglia; Zhe Tian; Ioana Popa; Alessandro Larcher; Malek Meskawi; Alberto Briganti; Michael McCormack; Shahrokh F Shariat; Francesco Montorsi; Markus Graefen; Fred Saad; Pierre I Karakiewicz
Journal:  Can Urol Assoc J       Date:  2016 Mar-Apr       Impact factor: 1.862

3.  A pilot phase II study of neoadjuvant triplet chemotherapy regimen in patients with locally advanced resectable colon cancer.

Authors:  Haitao Zhou; Yan Song; Jun Jiang; Haitao Niu; Hong Zhao; Jianwei Liang; Hao Su; Zheng Wang; Zhixiang Zhou; Jing Huang
Journal:  Chin J Cancer Res       Date:  2016-12       Impact factor: 5.087

4.  Population-based analysis of perioperative chemotherapy use, interventions requiring hospitalization and atheroembolic events among patients with non-metastatic muscle-invasive bladder cancer.

Authors:  Tarik Benidir; Jaime Herrera-Caceres; Christopher Wallis; Katherine Lajkosz; Neil Fleshner
Journal:  Cancer Med       Date:  2021-03-12       Impact factor: 4.452

5.  Inappropriate use of clinical practices in Canada: a systematic review.

Authors:  Janet E Squires; Danielle Cho-Young; Laura D Aloisio; Robert Bell; Stephen Bornstein; Susan E Brien; Simon Decary; Melissa Demery Varin; Mark Dobrow; Carole A Estabrooks; Ian D Graham; Megan Greenough; Doris Grinspun; Michael Hillmer; Tanya Horsley; Jiale Hu; Alan Katz; Christina Krause; John Lavis; Wendy Levinson; Adrian Levy; Michelina Mancuso; Steve Morgan; Letitia Nadalin-Penno; Andrew Neuner; Tamara Rader; Wilmer J Santos; Gary Teare; Joshua Tepper; Amanda Vandyk; Michael Wilson; Jeremy M Grimshaw
Journal:  CMAJ       Date:  2022-02-28       Impact factor: 16.859

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.